التفاصيل البيبلوغرافية
| العنوان: |
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms |
| المؤلفون: |
Nannya, Yasuhito, Tobiasson, Magnus, Sato, Shinya, Bernard, Elsa, Ohtake, Shigeki, Takeda, June, Creignou, Maria, Zhao, Lanying, Kusakabe, Manabu, Shibata, Yuhei, Nakamura, Nobuhiko, Watanabe, Mizuki, Hiramoto, Nobuhiro, Shiozawa, Yusuke, Shiraishi, Yuichi, Tanaka, Hiroko, Yoshida, Kenichi, Kakiuchi, Nobuyuki, Makishima, Hideki, Nakagawa, Masahiro, Usuki, Kensuke, Watanabe, Mitsumasa, Imada, Kazunori, Handa, Hiroshi, Taguchi, Masataka, Kiguchi, Toru, Ohyashiki, Kazuma, Ishikawa, Takayuki, Takaori-Kondo, Akifumi, Tsurumi, Hisashi, Kasahara, Senji, Chiba, Shigeru, Naoe, Tomoki, Miyano, Satoru, Papaemanuil, Elli, Miyazaki, Yasushi, Hellström-Lindberg, Eva, Ogawa, Seishi |
| المساهمون: |
南谷, 泰仁, 竹田, 淳恵, 趙, 蘭英, 渡邊, 瑞希, 塩澤, 裕介, 吉田, 健一, 垣内, 伸之, 牧島, 秀樹, 中川, 正宏, 髙折, 晃史, 小川, 誠司 |
| بيانات النشر: |
American Society of Hematology |
| سنة النشر: |
2023 |
| المجموعة: |
Kyoto University Research Information Repository (KURENAI) / 京都大学学術情報リポジトリ |
| مصطلحات موضوعية: |
Clinical Trials and Observations, Myeloid Neoplasia |
| الوصف: |
Azacitidine is a mainstay of therapy for MDS-related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their post-treatment clone size. We enrolled a total of 449 patients with MDS or related myeloid neoplasms. They were analyzed for gene mutations in pre- (n=449) and post- (n=289) treatment bone marrow samples using targeted-capture sequencing to assess the impact of gene mutations and their post-treatment clone size on treatment outcomes. In Cox proportional hazard modeling, multi-hit TP53 mutation (HR, 2.03; 95% CI, 1.42-2.91; P<.001), EZH2 mutation (HR, 1.71; 95% CI, 1.14-2.54; P=.009), and DDX41 mutations (HR, 0.33; 95% CI, 0.17-0.62; P<.001), together with age, high-risk karyotypes, low platelet, and high blast counts, independently predicted OS. Post-treatment clone size accounting for all drivers significantly correlated with International Working Group (IWG)-response (P<.001, trend test), except for that of DDX41-mutated clones, which did not predict IWG-response. Combined, IWG-response and post-treatment clone size further improved the prediction of the original model and even that of a recently proposed molecular prediction model, IPSS-M (c-index, 0.653 vs 0.688; P<.001, likelihood ratio test). In conclusion, evaluation of post-treatment clone size, together with pre-treatment mutational profile as well as IWG-response have a role in better prognostication of azacitidine-treated myelodysplasia patients. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| تدمد: |
2473-9529 |
| العلاقة: |
http://hdl.handle.net/2433/284567Test; Blood Advances; 14; 3624; 3636 |
| الإتاحة: |
http://hdl.handle.net/2433/284567Test |
| حقوق: |
© 2023 by The American Society of Hematology. ; Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ; https://creativecommons.org/licenses/by-nc-nd/4.0/legalcodeTest |
| رقم الانضمام: |
edsbas.F7EF03ED |
| قاعدة البيانات: |
BASE |
Full Text Finder